Acceleron A536-03 (#485)
Laufzeit: 01.01.2016 - 31.12.2019
imported
Kurzfassung
A phase 2, open-label, ascending dose study of ACE-536 for the
treatment of anemia in patients with low or intermediate-1 risk
Myelodysplastic Syndromes (MDS)
